Open AccessNiraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context
Author(s) -
Antonio González-Martín,
Ursula A. Matulonis,
Jacob Korach,
Mansoor Raza Mirza,
Kathleen Moore,
Xiaohua Wu,
Whitney York,
Dhiraj Gupta,
Stanislav Lechpammer,
Bradley J. Monk
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0206
Subject(s) - medicine , oncology , ovarian cancer , context (archaeology) , brca mutation , adverse effect , biomarker , clinical trial , cancer , biology , biochemistry , paleontology
We reviewed clinical data for niraparib monotherapy in BRCA -mutated ( BRCA m) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCA m versus non- BRCA m cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCA m OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).